Section one: Contracting authority
one.1) Name and addresses
University of Leeds
Worsley building L11, Level 11 Worsley Building, Clarendon Way
Leeds
LS2 9JZ
Contact
Fiona Coleman
Telephone
+44 1133434339
Country
United Kingdom
NUTS code
UKE42 - Leeds
Internet address(es)
Main address
one.2) Information about joint procurement
The contract is awarded by a central purchasing body
one.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge, at
https://www.delta-esourcing.com/tenders/UK-UK-Leeds:-Pharmaceutical-products./KN99DX49U3
Additional information can be obtained from the above-mentioned address
Tenders or requests to participate must be submitted electronically via
https://www.delta-esourcing.com/tenders/UK-UK-Leeds:-Pharmaceutical-products./KN99DX49U3
Tenders or requests to participate must be submitted to the above-mentioned address
one.4) Type of the contracting authority
Body governed by public law
one.5) Main activity
Education
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
Storage, Distribution and Labelling of Drugs for Clinical Trials
Reference number
2023-24-3489
two.1.2) Main CPV code
- 33600000 - Pharmaceutical products
two.1.3) Type of contract
Supplies
two.1.4) Short description
The Leeds Institute of Clinical Research at the University of Leeds (UoL) is seeking tenders for a supplier for the Storage, Distribution and Labelling of Drugs for Clinical Trials
This tender is made up of 3 Lots for 3 different trials
two.1.5) Estimated total value
Value excluding VAT: £250,000
two.1.6) Information about lots
This contract is divided into lots: Yes
Tenders may be submitted for all lots
Maximum number of lots that may be awarded to one tenderer: 3
two.2) Description
two.2.1) Title
Lot 1 (Trial 1) – SPECTRUM
Lot No
1
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UKE42 - Leeds
Main site or place of performance
Leeds
two.2.4) Description of the procurement
This trial is subject is currently awaiting a funding award based on the funding application. The outcome of this tender will be part of the final application as we are required to demonstrate that we have sought to provide the best value for money to the funding body.
The estimated start date for this trial is Q1 2025.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £50,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
22
This contract is subject to renewal
No
two.2.9) Information about the limits on the number of candidates to be invited
Envisaged minimum number: 2
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 2 (Trial 2) – IMMERSE
Lot No
2
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UKE42 - Leeds
Main site or place of performance
Leeds
two.2.4) Description of the procurement
The estimated start date for this trial is Dec 2024.
It is anticipated that 30 patients will be recruited to this trial over a period of 12 months (depending on patient recruitment rates) and patients will remain on treatment for a maximum of 36 months.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £200,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
48
This contract is subject to renewal
No
two.2.9) Information about the limits on the number of candidates to be invited
Envisaged minimum number: 2
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 3 (Trial 3) – BITTEN
Lot No
3
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UKE42 - Leeds
Main site or place of performance
Leeds
two.2.4) Description of the procurement
This trial is subject is currently awaiting a funding award based on the funding application. The outcome of this tender will be part of the final application as we are required to demonstrate that we have sought to provide the best value for money to the funding body.
The estimated start date for this trial is Summer 2025.
It is anticipated that 40 patients will be recruited to this trial over a period of 18 months (depending on patient recruitment rates) and patients will remain on treatment for a maximum of 12 months.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £200,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
36
This contract is subject to renewal
No
two.2.9) Information about the limits on the number of candidates to be invited
Envisaged minimum number: 2
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Competitive procedure with negotiation
four.1.4) Information about reduction of the number of solutions or tenders during negotiation or dialogue
Recourse to staged procedure to gradually reduce the number of solutions to be discussed or tenders to be negotiated
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: Yes
four.2) Administrative information
four.2.2) Time limit for receipt of tenders or requests to participate
Date
8 April 2024
Local time
10:00am
four.2.4) Languages in which tenders or requests to participate may be submitted
English
four.2.6) Minimum time frame during which the tenderer must maintain the tender
Duration in months: 3 (from the date stated for receipt of tender)
Section six. Complementary information
six.1) Information about recurrence
This is a recurrent procurement: No
six.3) Additional information
For more information about this opportunity, please visit the Delta eSourcing portal at:
https://www.delta-esourcing.com/tenders/UK-UK-Leeds:-Pharmaceutical-products./KN99DX49U3" target="_blank">https://www.delta-esourcing.com/tenders/UK-UK-Leeds:-Pharmaceutical-products./KN99DX49U3
To respond to this opportunity, please click here:
https://www.delta-esourcing.com/respond/KN99DX49U3" target="_blank">https://www.delta-esourcing.com/respond/KN99DX49U3
GO Reference: GO-2024226-PRO-25364687
six.4) Procedures for review
six.4.1) Review body
The High Court of England and Wales
The Strand, 1 - 3 Lifton Villas, Lifton Place
London
WC2A 2LL
Country
United Kingdom
six.4.2) Body responsible for mediation procedures
University of Leeds
Purchasing Office, Level 11 Worsley Building, Clarendon Way
Leeds
LS2 9JT
centralpurchasing@adm.leeds.ac.uk
Country
United Kingdom
six.4.4) Service from which information about the review procedure may be obtained
University of Leeds
Purchasing Office, Level 11 Worsley Building, Clarendon Way
Leeds
LS2 9JT
centralpurchasing@adm.leeds.ac.uk
Country
United Kingdom